GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » Quality Rank

CytomX Therapeutics (STU:6C1) Quality Rank


View and export this data going back to 2016. Start your Free Trial

What is CytomX Therapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

CytomX Therapeutics Quality Rank Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


CytomX Therapeutics Business Description

Traded in Other Exchanges
Address
151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.